Concurrent hypereosinophilic syndrome and deep vein thrombosis after Pfizer‐BioNTech COVID‐19 vaccination: A case report
Clinical Case Reports · 2023-03 · 11 (3)
DOI: 10.1002/ccr3.7001 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 02.03.2023. Verfasst von Shungo Yano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine Juntendo University Faculty of Medicine Tokyo Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Herein, we report a case of eosinophilia syndrome and deep vein thrombosis presenting concurrently after the administration of the BNT162b2 mRNA‐based coronavirus disease 2019 (COVID‐19) vaccine. It is extremely rare to have both hypereosinophilic syndrome and deep vein thrombosis simultaneously. Both are serious diseases and should be treated with caution.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Medicine Juntendo University Faculty of Medicine Tokyo Japan.
ORCID-Profile: Taiju Miyagami
Zitieren
APA
Yano, S., Miyagami, T., Furusaka, T., Kano, N., & Naito, T. (2023). Concurrent hypereosinophilic syndrome and deep vein thrombosis after Pfizer‐BioNTech COVID‐19 vaccination: A case report. Clinical Case Reports, 11(3). https://doi.org/10.1002/ccr3.7001
Vancouver
Yano S, Miyagami T, Furusaka T, Kano N, Naito T. Concurrent hypereosinophilic syndrome and deep vein thrombosis after Pfizer‐BioNTech COVID‐19 vaccination: A case report. Clinical Case Reports. 2023;11(3). doi:10.1002/ccr3.7001
BibTeX
@article{Yano2023,
author = {Yano, Shungo and Miyagami, Taiju and Furusaka, Takayuki and Kano, Nagamasa and Naito, Toshio},
title = {Concurrent hypereosinophilic syndrome and deep vein thrombosis after Pfizer‐BioNTech COVID‐19 vaccination: A case report},
journal = {Clinical Case Reports},
year = {2023},
volume = {11},
number = {3},
doi = {10.1002/ccr3.7001}
}
EUVIMED